Download PDF
Pharmacopsychiatry 2020; 53(02): 60-64
DOI: 10.1055/a-1071-8028
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Drug-Induced Liver Injury (DILI) in Patients with Depression Treated with Antidepressants: A Retrospective Multicenter Study

Bianca Ueberberg
1   Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, LWL-Klinik Dortmund, Dortmund, Germany
,
Ulrich Frommberger
2   Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Klinik an der Lindenhöhe, Offenburg, Germany
3   Department of Psychiatry and Psychotherapy, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
,
Thomas Messer
4   Danuviusklinik, Psychiatry, Pfaffenhofen, Germany
,
Peter Zwanzger
5   kbo Inn-Salzach-Klinikum, Psychiatry, Wasserburg/Inn, Germany
,
Jens Kuhn
6   Johanniter Krankenhaus Oberhausen, Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Oberhausen, Germany
,
Ion Anghelescu
7   Dr. Fontheim GmbH und Co KG, Mentale Gesundheit, Liebenburg, Germany
8   Blomenburg Mental Health Care, Psychiatrie, Psychotherapie und Psychosomatik, Selent, Germany
,
Katharina Ackermann
1   Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, LWL-Klinik Dortmund, Dortmund, Germany
,
Hans-Jörg Assion
1   Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, LWL-Klinik Dortmund, Dortmund, Germany
› Author Affiliations
Further Information

Publication History

received 02 July 2019
revised 08 November 2019

accepted 21 November 2019

Publication Date:
20 January 2020 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction Drug-induced liver injury (DILI) is the 4th most common cause of liver damage in Western countries and can be caused by antidepressants.

Methods Against the background of increasing antidepressant prescriptions and increasing use of polypharmacy, we analyzed administered antidepressants and other pharmacological substances, liver toxicity, comorbid somatic secondary diseases together with the occurrence of DILI in a patient population of 6 centers throughout Germany.

Results The majority of the enrolled 329 patients received polypharmacological treatment in an inpatient setting. During antidepressant treatment 5.1% of the patients had elevated serum transaminase levels, whereby exactly and not more than 1 criterion proposed to be indicative for DILI, was fulfilled by 3 patients (0.9%).

Discussion During patient characterization it becomes clear that a sensitization for relevant risk constellations causing liver injury in MDD patients is relevant to prevent further serious adverse events.

Key words

drug-induced liver injury - antidepressants - depression - liver injury - hepatic side effects

Supplementary Material

 

  • References

  • 1 Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 2009; 14: 162-167
    CrossrefPubMedGoogle Scholar
  • 2 Lewis JH. “Hy’s law,” the “Rezulin Rule,” and other predictors of severe drug-induced hepatotoxicity: Putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006; 15: 221-229
    CrossrefPubMedGoogle Scholar
  • 3 Watkins PB, Seeff LB. Drug-induced liver injury: Summary of a single topic clinical research conference. Hepatology 2006; 43: 618-631
    CrossrefPubMedGoogle Scholar
  • 4 Lee WM. Drug-induced acute liver failure. Clin Liver Dis 2013; 17: 575-586
    CrossrefPubMedGoogle Scholar
  • 5 Bechmann LP, Manka P, Best J. et al. Drug-induced liver injury as predominant cause of acute liver failure in a monocenter study. Dtsch Med Wochenschr 2014; 139: 878-882
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Aithal GP, Watkins PB, Andrade RJ. et al Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-815
    PubMedGoogle Scholar
  • 7 Food and Drug Administration USD of H and HS Guidance for industry drug–induced liver injury: Premarketing clinical evaluation. Drug Saf 2009.
    PubMed
  • 8 Lammert C, Einarsson S, Saha C. et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals. Hepatology 2008; 47: 2003-2009
    CrossrefPubMedGoogle Scholar
  • 9 Chalasani N, Bonkovsky HL, Fontana R. et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 2015; 147: 1340-1352
    PubMedGoogle Scholar
  • 10 Navarro VJ, Barnhart H, Bonkovsky HL. et al. Liver injury from herbals and dietary supplements in the U.S. drug-Induced liver injury network. Hepatology 2014; 60: 1399-1408
    CrossrefPubMedGoogle Scholar
  • 11 World Health Organisation Depression and other common mental disorders: Global health estimates. 2017
    PubMed
  • 12 Lohse MJ, Lorenzen A, Müller-Oerlinghausen B. Psychopharmaka. In: Arzneiverordnungs-Report 2004: Aktuelle daten, kosten, trends und kommentare. Berlin, Heidelberg: Springer; 2004: 769-810
    Google Scholar
  • 13 Voican CS, Corruble E, Naveau S. et al. Antidepressant-induced liver injury: A review for clinicians. Am J Psychiatry 2014; 171: 404-415
    CrossrefPubMedGoogle Scholar
  • 14 Friedrich ME, Akimova E, Huf W. et al. Drug-induced liver injury during antidepressant treatment: results of AMSP, a drug surveillance program. Int J Neuropsychopharmacol 2016; 19: 1-9
    PubMedGoogle Scholar
  • 15 Chang CY, Schiano TD. Review article: Drug hepatotoxicity. Aliment Pharmacol Ther 2007; 25: 1135-1151
    CrossrefPubMedGoogle Scholar
  • 16 World Health Organisation ICD-10 international statistical classification of diseases and related health problems. 2011
    PubMed
  • 17 Robles-Diaz M, Isabel Lucena M, Kaplowitz N et al. Use of hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014, doi:10.1053/j.gastro.2014.03.050
    PubMed
  • 18 Schmidt-Kraepelin C, Horstkötter E, Zielasek J. et al. Antidepressive combination treatment in patients with severe depressive episode: The practice of prescription in a clinical sample 2012. Psychiatr Prax 2017; 44: 247-278
    PubMedGoogle Scholar
  • 19 Ferrajolo C, Scavone C, Donati M. et al. Antidepressant-induced aute liver injury: A case–control study in an Italian inpatient population. Drug Saf 2018; 41: 95-102
    CrossrefPubMedGoogle Scholar
  • 20 Cipriani A, Furukawa TA, Salanti G. et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet 2018; 391: 1357-1366
    CrossrefPubMedGoogle Scholar
  • 21 Forns J, Pottegård A, Reinders T. et al. Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators. J Affect Disord 2019; 249: 242-252
    CrossrefPubMedGoogle Scholar
  • 22 Schienkiewitz A, Mensink GBM, Kuhnert R. et al. Übergewicht und Adipositas bei Erwachsenen. J Heal Monit 2017; 2: 21-27
    CrossrefPubMedGoogle Scholar
  • 23 Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment: Mechanisms and management. Drug Saf 1996; 14: 329-342
    CrossrefPubMedGoogle Scholar
  • 24 Zeiher J, Kuntz B, Lange C. Rauchen bei Erwachsenen in Deutschland. J Heal Monit 2017; 2: 59-65
    PubMedGoogle Scholar
  • 25 Boksa P. Smoking, psychiatric illness and the brain. J Psychiatry Neurosci 2017; 42: 147-149
    CrossrefPubMedGoogle Scholar
  • 26 Piontek D, Gomes de Matos E, Atzendorf J, Kraus L. (2016). Kurzbericht Epidemiologischer Suchtsurvey 2015. Tabellenband: Alkoholkonsum, episodisches Rauschtrinken und Hinweise auf klinisch relevanten Alkoholkonsum nach Geschlecht und Alter im Jahr 2015. München: IFT Institut für Therapieforschung.
    PubMed
  • 27 Kullak-Ublick GA, Andrade RJ, Merz M. et al. Drug-induced liver injury: Recent advances in diagnosis and risk assessment. Gut 2017; 66: 1154-1164
    CrossrefPubMedGoogle Scholar
  • 28 Pladevall-Vila M, Pottegård A, Schink T. Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: A cohort and nested case-control study using automated health data sources. CNS Drugs 2019; 33: 383-395
    CrossrefPubMedGoogle Scholar
  • 29 Telles-Correia D, Barbosa A, Cortez-Pinto H. et al. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World J Gastrointest Pharmacol Ther 2017; 8: 26-28
    CrossrefPubMedGoogle Scholar
  • 30 Mosedale M, Watkins PB. Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther 2017; 100: 469-480
    PubMedGoogle Scholar